Results from the University of New South Wales appeared in the New England Journal of Medicine. The co-lead investigator said the results show the need for more treatment options in chronic kidney disease.
Allopurinol, often prescribed to reduce serum uric acid in patients with chronic kidney disease (CKD), fared no better than placebo in slowing renal decline in a new randomized clinical trial.
Investigators from the University of New South Wales (UNSW) published results for the CKD-FIX trial June 25, 2020, in the New England Journal of Medicine. They reported that up to 20% of patients with CKD take allopurinol for its urate-lowering effects, even though there was no evidence it would halt the decline in patients’ estimated glomerular filtration rate (eGFR).1
“We found the kidney function declined at a similar rate in patients receiving allopurinol and those receiving placebo,” co-lead author Sunil Badve, MD, conjoint associate professor at UNSW Medicine and senior research fellow at The George Institute for Global Health, said in a statement.
The findings have “major implications,” Badve said, because unless CKD patients also have gout—which allopurinol can alleviate—there is no reason for them to take the drug. “Now we know that they are likely taking medication that is of no benefit to them, unless they have other conditions that allopurinol is effective against, like gout.”
Allopurinol, which was first developed in the 1950s to be used in as a therapy in patients with leukemia, was later found to have urate-lowering properties and came into use for this purpose in the 1960s. A 2018 retrospective cohort study in JAMA Internal Medicine found that in patients who had gout, the 300 mg dose of allopurinol was associated with a 13% lower risk of stage 3 CKD or higher compared with nonusers. Doses lower than 300 mg per day were not associated with renal decline.2
Findings
This time, however, allopurinol was tested in a head-to-head clinical trial. The study involved 363 patients with either stage 3 or 4 CKD but no history of gout. Patients had a urinary albmin:creatinine (A/C) ratio of 265 or above, or they had experienced an eGFR decrease of at 3.0 mL/min per 1.73 m2 of body-surface area in the prior 12 months. They were randomized to receive 100 mg to 300 mg of allopurinol per day or placebo. Primary outcome was the change in eGFR through 104 weeks.
At enrollment, mean eGFR of the study population was 31.7 mL/min per 1.73 m2, mean urine A/C ratio was 716.9, and mean serum urate level was 8.2 mg/dL. After 104 weeks, the mean eGFR did not change significantly between the 2 groups:
Allopurinol is known to have side effects, including skin rashes. In CKD-FIX the allopurinol group had slightly more serious adverse events (AEs): 84 of 182 patients (46%), while the plabebo group saw serious AEs in 79 of 181 patients (44%).
The investigators warned that patients taking allopurinol to lower blood urate levels should not stop treatment on their own but should discuss the findings with their physician.
Badve said the study points out the need for better treatment options for slowing the progression of CKD are limited and only partially effective. “There is a huge need for new treatments for this condition,” he said.
References
1. Badve SV, Pascoe EM, Tiku A, et al, for the CKD-FIX Study Investigators. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020; 382:2504-2513. doi:10.1056/NEJMoa1915833
2. Vargas-Santos AB, Peloquin CE, Zhang Y, Neogi T. Association of chronic kidney disease with allopurinol use in gout treatment. JAMA Intern Med. 2018;178(11):1526-1533. doi:10.1001/jamainternmed.2018.4463
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
Dr Madeleine McDowell Discusses How CKD Disparities, Social Challenges Impact Health Care Access
October 4th 2023Madeleine McDowell, MD, hopes these data insights will help change providers' behavior in terms of adopting earlier and more regular screening for chronic kidney disease (CKD).
Read More
Advocating for All Patients With Chronic Kidney Disease
April 26th 2022Chronic kidney disease is the fastest-growing noncontagious disease in the United States. On this episode of Managed Care Cast, we speak with Mike Spigler, vice president of patient support and education for the American Kidney Fund, who is spearheading the Unknown Causes of Kidney Disease Project, which aims to help underserved patients get to the root cause of their kidney disease, while also helping to solve this mystery for a broader patient population.
Listen